Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (PET)
Status and phase
Completed
Phase 1
Conditions
Healthy
Treatments
Radiation: 2-[18F]-F-A85380
Drug: AZD3480
Study type
Interventional
Funder types
Industry
Identifiers
Details and patient eligibility
About
The study is being performed in order to learn more about AZD3480 (potential as treatment for patients with Alzheimer's Disease) and to investigate how much of AZD3480 is bound to the nicotinic receptors in the brain at different concentrations of AZD3480 in blood, as well as to investigate the period of time for this binding.
Enrollment
9 patients
Sex
Male
Ages
20 to 80 years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Physically Healthy volunteers
- Genotyped with regard to CYP2D6
- Normal MRI scan at Visit 2
Exclusion criteria
- Known or suspected drug or alcohol abuse or positive drugs of abuse screen as judged by the investigator.
- Participation in a PET examination as part of a scientific study during the past twelve months.
- Prescribed or non-prescribed from two weeks prior to the first PET examination. Occasional paracetamol and nasal spray for congestion will be allowed as medication.
Trial design
Primary purpose
Treatment
Allocation
Non-Randomized
Interventional model
Single Group Assignment
Masking
None (Open label)
9 participants in 2 patient groups
1
Experimental group
Treatment:
Drug: AZD3480
2
Experimental group
Treatment:
Radiation: 2-[18F]-F-A85380
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems